Accel-Rx Portfolio Companies Secure $40 Million Follow-On Funding

Accel-Rx announced that three of its portfolio companies - Kisoji Biotechnology, Soundbite Medical Solutions and Zucara Therapeutics - have secured a total of $40 million CDN in follow-on funding to advance the development and commercialization of their technologies.

Click here for more details.

 

Previous
Previous

Recapping 'How Do VCs Value Health Science Companies? From Valuation to Deal Structure'

Next
Next

New Guide Addresses Procurement Myths to Promote Innovation Adoption in Ontario